secwatch.observer — SEC 8-K summary
======================================

Issuer:     CapsoVision, Inc (CV)
CIK:        0001378325
Form:       8-K
Filed at:   2026-05-14T20:08:08+00:00
Accession:  0001378325-26-000019
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CapsoVision Q1 revenue flat at $2.8M; gross margin slides to 48% on tariffs
---------------------------------------------------------------------------

- Total revenue $2.8M, flat YoY; capsule volume down 3% offset by higher ASP.
- Gross margin 48% vs 54% YoY due to impact of U.S. trade policies and tariffs.
- Operating expenses $8.4M, up $1.5M from CMOS sensor development with Canon and Colon clinical trials.
- Cash $17.9M; completed $14M PIPE financing on March 16, 2026.
- Pipeline: AI-assisted reading feature on track for mid-2026 FDA clearance; CapsoCam Colon 510(k) submission Q3 2026; pancreatic cancer study enrolled first patient May 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1378325/000137832526000019/0001378325-26-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1378325/000137832526000019/cv-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001378325-26-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer